New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 23, 2013
10:35 EDTLLYEli Lilly drops after cancer drug data seen as 'underwhelming'
Eli Lilly (LLY) is retreating after the company reported a median overall survival rate of 5.2 months for patients who received the company's gastric cancer treatment, ramucirumab, in an abstract posted last night on the American Society of Clinical Oncology’s website. Patients who received a placebo had a median overall survival rate of 3.8 months. Although the overall survival rate produced by the drug was statistically significant, Leerink Swann analyst Seamus Fernandez called the data "somewhat underwhelming" in a note to investors earlier today. The company may still seek FDA approval for ramucirumab, but the agency will likely require the company to conduct another study before it will approve the drug, the analyst believes. Fernandez maintained an Outperform rating on the stock, which slid $1.10 ,or 2.06%, to $52.34 in mid-morning trading.
News For LLY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 27, 2015
08:32 EDTLLYEli Lilly's Humalog KwikPen approved by FDA
Subscribe for More Information
May 22, 2015
10:52 EDTLLYJPMorgan says Actavis shares cheap compared to peers
Subscribe for More Information
May 21, 2015
07:37 EDTLLYPfizer replaces AbbVie as top global pharma pick at Jefferies
Subscribe for More Information
May 14, 2015
09:22 EDTLLYLeerink pharma/biotech analysts hold an analyst/industry conference call
Subscribe for More Information
07:44 EDTLLYInternational Headache Society to hold a conference
17th Congress of the International Headache Society is being held in Valencia, Spain on May 14-17.
06:04 EDTLLYEli Lilly, Sanford-Burnham to investigate immunological therapies
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use